Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Normol A:Basic treatment: Salbutamol aerosol when need, 100-200ug a time, aerosol inhalation
if not satisfied with the effects, plus the aminophylline sustained-release tablets 0.1g, Bid, PO
other drugs for COPD are forbidden.
Test A:The same therateupics with the control for A Test Group plus Yiqigubiao Pills
Normol B:If the drugs like Seretide or Spiriva etc, are used before the trail, any change about the drugs, the dosage and the formulations is forbidden
if no drugs used before the trail and the diseas are controllable, no drugs will be subjoined
if no drugs used before the trail, but the diseas out of controlling, the Seretide 50/250ug Bid or Spiriva QD will be given, plus aminophylline 0.1g, PO, according to the disease. and the case will be
Test B:The same therateupics with the control for B Test Group plus Yiqigubiao Pills
Normol C:If the drugs like Seretide or Spiriva etc, are used before the trail, any change about the drugs, the dosage and the formulations is forbidden
if no drugs used before the trail, but the diseas out of controlling, the Seretide 50/250ug Bid or Spiriva QD will be given, plus aminophylline 0.1g, PO, according to the disease and the case will be
Test C:The same therateupics with the control for C Test Group plus Yiqigubiao Pills
Normol D:Basic treatment:Seretide 50/250ug,inhalation,Bid
if out of controlling,plus the Spiriva 18ug,inhalation,QD
or the aminophylline will be added,0.1g,PO,Bid.nd the case will be accepted after 4-6wks when the disease turn to be stable pahse,also any change about the drugs,the dosage and the formulations is for
the Salbutamol aerosol will be given when need,100-200ug,aerosol inhalation.other drugs for COPD are forbidden.
Test D:The same therateupics with the control for D Test Group
Sponsors
The Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Volunteers; 2. Age from 40-80 years; 3. Patients corresponding to diagnosis standards of stable COPD (types of A, B, C, D) ; 4. Patients corresponding to diagnosis standards of Lung Distension (syndrome of Deficiency of Lung-Spleen Qi and Obstruction of the Lung by Phlegm).
Exclusion criteria
Exclusion criteria: 1. Patients with pneumothorax, pleural effusion, lung cancer, active tuberculosis and other serious lung disease; 2. Patients with serious cardiovascular, primary disease of liver, kidney, hematopoietic system; 3. Acute exacerbation of chronic obstructive pulmonary disease; 4. When screening inspection the ALT/AST value was 1.5 times of the upper normal limit; 5. Patients with psychosis; 6. Women in stage of pregnant or lactation; 7. People with allergies or multiple drug allergy; 8. Patients with tumors; 9. People with congenital or acquired immunodeficiency; 10. Patients participate in other clinical trials in the recent month;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 6-minute walking distance;ModifiedMedical Research Council Scale,MMRC;COPD assessment test, CAT;the times and severity of exacerbation;rate of hospitalization;TCM symptom mark; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary Function;IL-6,8;TNF-alpha;CD4, CD; | — |
Countries
China
Contacts
Public ContactLi Feng-sen
Outcome results
None listed